Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin Re-treatment in Recurrent Ovarian and Related Cancers
NCT00866723Phase 2Terminated
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Mar 2009
- Primary completion
- Dec 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in epithelial ovarian cancer (EOC), primary peritoneal serous carcinoma (PPSC), serous endometrial carcinoma (UPSC), fallopian tube cancer (PFTC), sponsored by Beth Israel Deaconess Medical Center. Started Mar 2009; status: terminated.
02
Drugs
bevacizumab
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal serous carcinoma (PPSC)serous endometrial carcinoma (UPSC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00866723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00866723.